Drug Trial Radar · NCT04556656
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
499
Actual
Start
Oct 16, 2020
Primary completion
Mar 14, 2023
Study completion Mar 21, 2024
Sponsor
- Lead sponsor
- PrileniaIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).
Conditions
- Huntington Disease
Interventions
PridopidineDrug
Pridopidine hard gelatin capsule
PlaceboDrug
Pridopidine-matching placebo hard gelatin capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)Time frame: From baseline to Week 65
- Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)Time frame: From baseline to Week 65.
Locations
58 sites in 11 countries. Site status is shown where the registry gives one.
Prilenia Investigational Site (Site 061)
Davis, California
Prilenia Investigational Site (Site 051)
San Diego, California
Prilenia Investigational Site (Site 343)
Englewood, Colorado
Prilenia Investigational Site (Site 333)
Washington D.C., District of Columbia
Prilenia Investigational Site (Site 160)
Gainesville, Florida
Prilenia Investigational Site (Site 019)
Tampa, Florida
Prilenia Investigational Site (Site 032)
Atlanta, Georgia
Prilenia Investigational Site (Site 088)
Chicago, Illinois
Prilenia Investigational Site (Site 029)
Kansas City, Kansas
Prilenia Investigational Site (Site 083)
Wichita, Kansas
Prilenia Investigational Site (Site 087)
Louisville, Kentucky
Prilenia Investigational Site (Site 028)
Baltimore, Maryland
Prilenia Investigational Site (Site 017)
Boston, Massachusetts
Prilenia Investigational Site (Site 076)
Boston, Massachusetts
Prilenia Investigational Site (Site 027)
St Louis, Missouri
Prilenia Investigational Site (Site 037)
Albany, New York
Prilenia Investigational Site (Site 002)
New York, New York
Prilenia Investigational Site (Site 119)
Durham, North Carolina
Prilenia Investigational Site (Site 089)
Cincinnati, Ohio
Prilenia Investigational Site (Site 020)
Columbus, Ohio
Prilenia Investigational Site (Site 006)
Portland, Oregon
Prilenia Investigational Site (Site 018)
Philadelphia, Pennsylvania
Prilenia Investigational Site (Site 031)
Nashville, Tennessee
Prilenia Investigational Site (Site 199)
Houston, Texas
Prilenia Investigational Site (Site 326)
Richmond, Virginia
Prilenia Investigational Site (Site 096)
Seattle, Washington
Prilenia Investigational site (Site 291)
Innsbruck, Austria
Prilenia Investigational Site (Site 232)
Halifax, Canada
Prilenia Investigational Site (Site 030)
Calgary, Alberta, Canada
Prilenia Investigational Site (Site 048)
Vancouver, British Columbia, Canada
Prilenia Investigational Site (Site 098)
Montreal, Quebec, Canada
Prilenia Investigational Site (Site 388)
Prague, Czechia
Prilenia Investigational Site (Site 385)
Lille, France
Prilenia Investigational Site (Site 384)
Marseille, France
Prilenia Investigational Site (Site 392)
Paris, France
Prilenia Investigational Site (Site 234)
Aachen, Germany
Prilenia Investigational Site (Site 379)
Bochum, Germany
Prilenia Investigational Site (Site 377)
Lübeck, Germany
Prilenia Investigational Site (Site 376)
Münster, Germany
Prilenia Investigational site (Site 292)
Taufkirchen, Germany
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.